B

Bristol-Myers Squibb portfolio

Bristol-Myers Squibb has 4 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months. Its most recent investment on record is Cellares's $257M Series B+ round in January 2026, alongside Willett Advisors LLC, Koch Disruptive Technologies, Eclipse and 3 others. By category, its portfolio leans toward Health and bio (4) and Manufacturing and industrial (1). It has co-invested with Janus Henderson Investors, RA Capital Management and Eclipse, most often Janus Henderson Investors (2 rounds).

What Bristol-Myers Squibb invests in

• Health and bio · 4 · 100%
• Manufacturing and industrial · 1 · 25%

Bristol-Myers Squibb recent investments

Company	Round	Date	Alongside
CCellares	Series B+ · $257M	Jan 28, 2026	Willett Advisors LLC, Koch Disruptive Technologies (lead), Eclipse +3
GGlycoEra	Series B+ · $130M	May 27, 2025	Sofinnova Partners, Sixty Degree Capital, Roche Venture Fund +6
AAktis Oncology	Series B+ · $180M	Sep 1, 2024	T. Rowe Price, RTW Investments (lead), RA Capital Management (lead) +4
AAsher Bio	Series B+ · $55M	Apr 16, 2024	Wellington Management, Third Rock Ventures, RA Capital Management (lead) +3
AAktis Oncology	Series A · $72M	Mar 18, 2021	Vida Ventures (lead), TCG Crossover, Octagon Capital Advisors +3

How Bristol-Myers Squibb invests

Share is of the 5 rounds on Recent Funding that name Bristol-Myers Squibb. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Bristol-Myers Squibb portfolio companies

• CCellares$257MSeries B+ · Jan 2026
• GGlycoEra$130MSeries B+ · May 2025
• AAktis Oncology$180MSeries B+ · Sep 2024
• AAsher Bio$55MSeries B+ · Apr 2024

Company	Round with Bristol-Myers Squibb	Total raised	Latest raise
CCellares Health and bio	Jan 28, 2026 Series B+ · $257M	$357M	Jul 16, 2026 Series B+
GGlycoEra Health and bio	May 27, 2025 Series B+ · $130M	$179M	May 27, 2025 Series B+
AAktis Oncology Health and bio	Sep 1, 2024 Series B+ · $180M	$336M	Sep 1, 2024 Series B+
AAsher Bio Health and bio	Apr 16, 2024 Series B+ · $55M	$218M	Apr 16, 2024 Series B+

Most frequent co-investors

• JJanus Henderson Investors2 shared rounds · last Sep 1, 2024
• RRA Capital Management2 shared rounds · last Sep 1, 2024
• EEclipse1 shared round · last Jan 28, 2026
• 88VC1 shared round · last Jan 28, 2026
• DDFJ Growth1 shared round · last Jan 28, 2026
• WWillett Advisors LLC1 shared round · last Jan 28, 2026
• DDecheng Capital1 shared round · last Jan 28, 2026
• KKoch Disruptive Technologies1 shared round · last Jan 28, 2026
• CCatalio1 shared round · last May 27, 2025
• QQatar Investment Authority1 shared round · last May 27, 2025
• NNovo Holdings1 shared round · last May 27, 2025
• LLifeArc Ventures1 shared round · last May 27, 2025

Similar investors

• BBain Capital Life Sciences4 companies · 3 deals in 12 mo
• DDuquesne Family Office4 companies · 3 deals in 12 mo
• QQatar Development Bank4 companies · 3 deals in 12 mo
• TThe Column Group4 companies · 3 deals in 12 mo
• AAdage Capital Management4 companies · 2 deals in 12 mo
• AAsabys Partners4 companies · 2 deals in 12 mo

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

Portfolio companies are the companies on Recent Funding with a round that lists Bristol-Myers Squibb, which is a subset of its real portfolio. API: /api/v1/investors/bristol-myers-squibb (get a free API key). More: the most active VC firms and new venture capital funds.